Skip to main content

Galectin Therapeutics Inc PRE 14A, filed Oct 2, 2026

Galectin Therapeutics Inc (GALT)

Galectin Therapeutics will hold its virtual annual meeting on December 3, 2026, seek approval to increase authorized common shares from 150,000,000 to 250,000,000 and reserve an additional 3,000,000 shares under its 2019 Omnibus Equity Incentive Plan, and elect eleven directors. AI summary

PRE 14A 2026-10-02 For: 2026-12-03
View Original
Added on October 15, 2026